Hereditary Angioedema (HAE) (DBCOND0034226)

Identifiers

Synonyms
Angio Edema Hereditary / HAE / Hereditary Angioedema, HAE / Angioedema, Hereditary / Angioedemas, Hereditary / Hereditary Angioedema / Hereditary Angioedemas / Hereditary angioedema C1 inhibitor deficiency / Hereditary angioneurotic edema (disorder) / C1 esterase inhibitor deficiency

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Danazol
A synthetic steroid and pituitary gonadotropin inhibitor used in the treatment of endometriosis and symptomatic treatment of severe pain and tenderness associated with benign fibrocystic breasts.
Lanadelumab
A monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema.
Stanozolol
An anabolic steroid used to manage hereditary angioedema.
Tranexamic acid
An antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT05776784
Status of Dental Care Practices in Patients With Hereditary AngioedemaNo drug interventionsNot AvailableNot Availablerecruiting
NCT04933721
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studiesprevention3active_not_recruiting
NCT03029728
Biomarker for Hereditary AngioEdema DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT03485911
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAEprevention3completed
NCT02303626
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacksprevention2 / 3completed
NCT05121376
A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaNo drug interventionstreatment1 / 2active_not_recruiting
NCT04428632
Oral Berotralstat Expanded Access ProgramNot AvailableNot Availableapproved_for_marketing
NCT02670720
Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedemaprevention3terminated
NCT03472040
A Long Term Safety Study of BCX7353 in Hereditary Angioedemaprevention2 / 3completed
NCT03873116
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japanprevention3completed
NCT04057131
FIRAZYR General Drug Use-Results Survey (Japan)Not AvailableNot Availablecompleted
NCT05509569
A Survey of Icatibant in Pediatric Participants with Hereditary AngioedemaNot AvailableNot Availablerecruiting
NCT05469789
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)No drug interventionsNot AvailableNot Availablerecruiting
NCT06587464
A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean PeopleNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT02663687
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult SubjectsNo drug interventionstreatment1completed
NCT04583007
Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsNot AvailableNot Availableno_longer_available
NCT00457015
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)treatment3completed
NCT03845400
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North AmericaNo drug interventionsNot AvailableNot Availablecompleted
NCT02584959
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedemaprevention3completed
NCT05819775
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedematreatment3recruiting
NCT01826916
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedematreatment2completed
NCT02741596
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEprevention3completed
NCT05460325
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)treatment3completed
NCT01253382
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedematreatment2 / 3withdrawn
NCT05397431
A Survey of Lanadelumab in Participants With Hereditary AngioedemaNot AvailableNot Availablerecruiting
NCT01034969
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)No drug interventionsNot AvailableNot Availablerecruiting
NCT04861090
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term ProphylaxisNo drug interventionsNot AvailableNot Availablecompleted
NCT02045264
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteerstreatment1completed
NCT03240133
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedematreatment2completed
NCT02586805
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEprevention3completed
NCT01923207
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjectstreatment1completed
NCT06346899
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaNo drug interventionsNot AvailableNot Availablerecruiting
NCT02052141
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedemaprevention3completed
NCT05578417
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaNo drug interventionsNot AvailableNot Availablecompleted
NCT01386658
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedematreatment3completed
NCT04180163
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)treatment3completed
NCT01756157
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacksprevention2completed
NCT01059526
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary AngioedemaNot AvailableNot Availablecompleted
NCT02865720
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)treatment3completed
NCT04130191
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or IINo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT00262080
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)treatment3completed
NCT05489640
A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at HomeNo drug interventionsNot AvailableNot Availablecompleted
NCT02870972
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedemaprevention2completed
NCT01095510
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12treatment2completed
NCT05147181
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in PolandNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT03888755
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participantstreatment3completed
NCT01541423
A European Post-Authorisation Observational Study Of Patients With Hereditary AngioedemaNo drug interventionsNot AvailableNot Availablecompleted
NCT02093923
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participantstreatment1completed
NCT00456508
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)treatment3completed
NCT06210698
Angioedema Biomarker Research StudyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT04955964
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in ArgentinaNo drug interventionsNot AvailableNot Availablecompleted
NCT06007677
A Long-term Study of STAR-0215 in Participants with Hereditary AngioedemaNo drug interventionstreatment2recruiting
NCT06262399
Long-Term Follow-Up (LTFU) of Subjects Treated with NTLA 2002No drug interventionsNot AvailableNot Availableenrolling_by_invitation
NCT06343779
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaNo drug interventionstreatment3recruiting
NCT06634420
HAELO: a Phase 3 Study to Evaluate NTLA-2002 in Participants with Hereditary Angioedema (HAE)treatment3recruiting
NCT06628713
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatNot AvailableNot Availableavailable
NCT05139810
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)treatment3completed
NCT05396105
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedematreatment2 / 3enrolling_by_invitation
NCT06467084
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or IItreatment3recruiting
NCT04739059
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacksprevention3active_not_recruiting
NCT05120830
NTLA-2002 in Adults With Hereditary Angioedema (HAE)treatment1 / 2active_not_recruiting
NCT06573723
Institutional Registry of Rare DiseasesNo drug interventionsNot AvailableNot Availablerecruiting
NCT01188564
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksNo drug interventionstreatment3completed
NCT00748202
Berinert P Study of Subcutaneous Versus Intravenous AdministrationNot Available3completed
NCT03202784
A Relative Bioavailability Study of Two Formulations of BCX7353treatment1completed
NCT02854397
Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric PopulationNo drug interventionsNot AvailableNot Availableterminated
NCT03712228
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)prevention2completed
NCT00289211
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksNo drug interventionstreatment3completed
NCT05047185
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIprevention2active_not_recruiting
NCT06414252
Social Evaluated Cold Pressor Test in Hereditary Angioedema PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT04349800
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteerstreatment1completed
NCT04656418
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacksprevention3completed
NCT05505916
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)treatment3active_not_recruiting
NCT05118958
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsNo drug interventionstreatment1completed
NCT01151735
C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationNo drug interventionstreatment4withdrawn
NCT01426763
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidaseother2completed
NCT05511922
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trialtreatment3recruiting
NCT02159430
Hereditary AngioEdema, Neurobiology and PsychopathologyNo drug interventionsNot AvailableNot Availableunknown_status
NCT04070326
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Childrenprevention3completed
NCT05477160
A Study of STAR-0215 in Healthy Adult ParticipantsNo drug interventionstreatment1completed
NCT05453968
Berotralstat Treatment in Children With Hereditary Angioedematreatment3active_not_recruiting
NCT01359969
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patientstreatment2completed
NCT04208412
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IItreatment2completed
NCT01679912
A Call Center During HAE Attacks (SOS HAE)No drug interventionstreatment4completed
NCT00292981
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)treatment3completed
NCT04307381
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedematreatment2active_not_recruiting
NCT05392114
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)treatment3recruiting
NCT00168103
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attackstreatment2 / 3completed
NCT02448264
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteerstreatment1completed
NCT01397864
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksNot AvailableNot Availablerecruiting
NCT02819102
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substratestreatment1completed
NCT03697187
Patient Registry to Evaluate the Real-world Safety of Ruconest®Not AvailableNot Availablecompleted
NCT04654351
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedematreatment3completed
NCT00225147
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedematreatment2 / 3completed
NCT04030598
A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedematreatment2completed
NCT06408805
Autonomic Nervous System Profile in Hereditary AngioedemaNo drug interventionsNot AvailableNot Availablecompleted
NCT01095497
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administrationother2completed
NCT05691361
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema PatientsNo drug interventionstreatment1recruiting
NCT04618211
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedematreatment2completed
NCT00912093
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)treatment3completed
NCT01984788
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAEprevention2completed
NCT01005888
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksNo drug interventionsprevention3completed
NCT00851409
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administrationtreatment2completed
NCT04898309
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedematreatment2 / 3withdrawn
NCT00462709
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksNo drug interventionsprevention3completed
NCT00500656
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)treatment3completed
NCT00438815
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksNo drug interventionstreatment3completed
NCT04687137
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedematreatment3completed
NCT03136237
A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactionstreatment1completed
NCT04091113
Hereditary Angioedema Kininogen AssayNo drug interventionsNot AvailableNot Availableterminated
NCT04557319
Safety and Pharmacokinetics of GNR-038 in Healthy VolunteersNo drug interventionsother1completed
NCT04957641
A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary AngioedemaNo drug interventionsNot AvailableNot Availablecompleted
NCT05259917
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)treatment3completed
NCT02247739
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitorprevention2completed
NCT01457430
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAEtreatment4completed
NCT05695248
A Study of STAR-0215 in Participants With Hereditary AngioedemaNo drug interventionstreatment1 / 2active_not_recruiting
NCT06415448
Donidalorsen Expanded Access Program for Patients With Hereditary AngioedemaNot AvailableNot Availableavailable
NCT00914966
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZEprevention4completed
NCT02218294
Study to Determine How BCX4161 is Metabolized and Eliminated by the Bodytreatment1completed
NCT02125162
A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161treatment1completed
NCT00262301
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedematreatment3completed
NCT00997204
EASSI - Evaluation of the Safety of Self-Administration With Icatibanttreatment3completed
NCT00432510
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsNo drug interventionsother1completed
NCT05178355
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersNo drug interventionstreatment1completed
NCT04888650
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary AngioedemaNo drug interventionsNot AvailableNot Availablecompleted